Financials data is unavailable for this security.
View more
Year on year Celldex Therapeutics Inc had net income fall 25.91% from a loss of 112.33m to a larger loss of 141.43m despite a 192.02% increase in revenues from 2.36m to 6.88m.
| Gross margin | -- |
|---|---|
| Net profit margin | -1,544.48% |
| Operating margin | -1,871.27% |
| Return on assets | -27.93% |
|---|---|
| Return on equity | -29.84% |
| Return on investment | -29.53% |
More ▼
Cash flow in USDView more
In 2023, Celldex Therapeutics Inc increased its cash reserves by 18.30%, or 5.39m. Cash Flow from Financing totalled 218.46m or 3,173.88% of revenues. In addition the company used 107.29m for operations while cash used for investing totalled 105.78m.
| Cash flow per share | -2.48 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 11.85 |
|---|---|
| Tangible book value per share | 11.44 |
More ▼
Balance sheet in USDView more
| Current ratio | 24.27 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
